These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1102 related articles for article (PubMed ID: 17671692)
1. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
2. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270 [TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Tsapis M; Lieb M; Manzo F; Shankaranarayanan P; Herbrecht R; Lutz P; Gronemeyer H Int J Biochem Cell Biol; 2007; 39(7-8):1500-9. PubMed ID: 17499001 [TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020 [TBL] [Abstract][Full Text] [Related]
6. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934 [TBL] [Abstract][Full Text] [Related]
7. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350 [TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997 [TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791 [TBL] [Abstract][Full Text] [Related]
10. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Huang L; Sowa Y; Sakai T; Pardee AB Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357 [TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901 [TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424 [TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433 [TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Xu Y; Voelter-Mahlknecht S; Mahlknecht U Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844 [TBL] [Abstract][Full Text] [Related]
15. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398 [TBL] [Abstract][Full Text] [Related]
17. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487 [TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644 [TBL] [Abstract][Full Text] [Related]
19. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Seo SK; Jin HO; Lee HC; Woo SH; Kim ES; Yoo DH; Lee SJ; An S; Rhee CH; Hong SI; Choe TB; Park IC Mol Pharmacol; 2008 Mar; 73(3):1005-12. PubMed ID: 18156316 [TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]